Helus Pharma Inc 6-K/A, filed Nov 13, 2023
Helus Pharma Inc. (HELP)
About this 6-K/A
Helus Pharma Inc filed this 6-K/A on November 13, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K/A
Amendment No. 1
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2023.
Commission File Number: 001-40673
Cybin Inc.
(Exact Name of Registrant as Specified in Charter)
100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F □ Form 40-F ⊠
EXPLANATORY NOTE
Cybin Inc. (the "Company") is filing this Amendment No. 1 on Form 6-K/A (the "Amendment") solely to incorporate by reference Exhibit 99.1 to this Amendment into the registrant's Registration Statement on Form F-10 (File No. 333-272706). Except as set forth herein, the remainder of the version originally filed with the Securities and Exchange Commission on October 23, 2023 remains unchanged.
INCORPORATION BY REFERENCE
Exhibit 99.1 of this Amendment of the Company is hereby incorporated by reference into the Registration Statement on Form F-10 (File No. 333-272706) of the Company, as amended or supplemented.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CYBIN INC. | |||
| (Registrant) | |||
| Date: | November 13, 2023 | By: | /s/ Doug Drysdale |
| Name: | Doug Drysdale | ||
| Title: | Chief Executive Officer | ||
EXHIBIT INDEX
| 99.1* | News Release dated October 23, 2023 |
| * | Previously filed. |